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Abstract
The uremic toxins indoxyl sulfate (IS) and p-cresyl sulfate (pCS) accumulate in patients with
chronic kidney disease (CKD) as a consequence of altered gut microbiota metabolism and a
decline in renal excretion. Despite of solid experimental evidence for nephrotoxic effects,
the impact of uremic toxins on the progression of CKD has not been investigated in repre-
sentative patient cohorts. In this analysis, IS and pCS serum concentrations were measured
in 604 pediatric participants (mean eGFR of 27 ± 11 ml/min/1.73m2) at enrolment into the
prospective Cardiovascular Comorbidity in Children with CKD study. Associations with pro-
gression of CKD were analyzed by Kaplan-Meier analyses and Cox proportional hazard
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models. During a median follow up time of 2.2 years (IQR 4.3–0.8 years), the composite
renal survival endpoint, defined as 50% loss of eGFR, or eGFR <10ml/min/1.73m2 or start
of renal replacement therapy, was reached by 360 patients (60%). Median survival time was
shorter in patients with IS and pCS levels in the highest versus lowest quartile for both IS
(1.5 years, 95%CI [1.1,2.0] versus 6.0 years, 95%CI [5.0,8.4]) and pCS (1.8 years, 95%CI
[1.5,2.8] versus 4.4 years, 95%CI [3.4,6.0]). Multivariable Cox regression disclosed a signifi-
cant association of IS, but not pCS, with renal survival, which was independent of other risk
factors including baseline eGFR, proteinuria and blood pressure. In this exploratory analysis
we provide the first data showing a significant association of IS, but not pCS serum concen-
trations with the progression of CKD in children, independent of other known risk factors. In
the absence of comorbidities, which interfere with serum levels of uremic toxins, such as
diabetes, obesity and metabolic syndrome, these results highlight the important role of ure-
mic toxins and accentuate the unmet need of effective elimination strategies to lower the
uremic toxin burden and abate progression of CKD.
Introduction
Identifying modifiable risk factors for the continuous loss of renal function that characterizes
chronic kidney disease (CKD) is a major challenge towards improving treatment for patients
with CKD. While hypertension and proteinuria are established risk factors for progression of
CKD both in adults and children, even optimal current treatment still cannot prevent many
patients progressing to end-stage kidney disease [1–3].
CKD leads to alterations in the gut microbiome (dysbiosis) and accumulation of gut
derived uremic toxins in plasma [4]. We have previously shown that the uremic toxins indoxyl
sulfate (IS) and p-cresyl sulfate (pCS) are inversely correlated to the estimated glomerular fil-
tration rate (eGFR) in children and adolescents across all stages of CKD [5].
The accumulation of these toxins in the circulation has deleterious consequences, as
their plasma concentrations are associated with cardiovascular events in adult CKD patients
and with surrogate markers of cardiovascular disease (CVD) in pediatric patients [5, 6]. In
addition, uremic toxins may affect kidney cells directly and thus promote progression of
CKD. IS and pCS have direct toxic effects on tubular epithelial cells in vitro [7]. In animal
models the accumulation of these toxins in renal tubular cells has been demonstrated to
cause direct cytotoxicity, tubulointerstitial fibrosis and acceleration of CKD progression [8,
9]. While there is experimental evidence both in vitro and in vivo for nephrotoxic effects of
uremic toxins, associations of IS and pCS serum levels with progression of CKD have only
been investigated in a single study of adult CKD patients to date [10]. Here we investigated
the impact of IS and pCS on progression of CKD in a cohort of more than 600 children with




The 4C study is a prospective observational cohort study conducted at 55 pediatric nephrology
centers in 12 European countries. Children with an initial eGFR of 10–60 ml/min per 1.73m2
were included in the study. Written informed consent was obtained from all patients and/or
parents. The study was approved by the Ethics Board of the University of Heidelberg (S-032/
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2009) and subsequently by the local review boards of each participating institution (for a com-
plete list of review boards, see [11]). All procedures performed involving human participants
were in accordance with the Declaration of Helsinki. Additional details, including exclusion
criteria, have been published in detail previously [12].
In the 4C study all participating centers were visited annually by trained regional coordina-
tors. Every 6 months an update of the medical history and medication, clinical status and
anthropometric data were obtained and blood and urine samples were collected and stored for
central laboratory analysis. Office systolic blood pressure (SBP) was documented as an average
of three oscillometric measurements using local devices. SBP and body mass index (BMI) were
normalized for height and age (SBP SDS and BMI SDS respectively) as previously described.
[12]. Glomerular filtration rate was estimated (eGFR) using the 2009 bedside Schwartz formula
[13]. Patients were categorized according to their country of residency as Mediterranean (Tur-
key, Portugal, France and Italy) and non-Mediterranean (Germany, Austria, Switzerland,
Poland, Lithuania, Serbia, Czech Republic and United Kingdom). Renal diagnoses were
grouped into congenital anomalies of the kidney and urinary tract (CAKUT), tubulointerstitial
disorders, glomerulopathies, chronic kidney disease after acute kidney injury (post-AKI CKD)
and others.
Laboratory methods
Serum samples were available in 604 patients at the baseline visit. Total serum levels of IS and
pCS were measured centrally using reverse-phase separation and fluorescence detection, as
described previously [5].
Statistical analyses
Baseline characteristics are given as mean ± standard deviation (SD), median with interquar-
tile range (IQR) or frequencies (n, %), as appropriate. Serum concentrations of IS and pCS
measured at the baseline visit were used to analyze an association with renal survival time dur-
ing follow up. Summary statistics stratified by CKD stage are provided for IS and pCS. As the
distribution of IS and pCS was skewed, these variables were log transformed for further analy-
sis. The assumption of normal distributed data was proven (visual inspection and comprehen-
sive summary statistic) after log transformation. Correlation of IS and pCS (log transformed)
with eGFR was quantified by means of Pearson correlation coefficient. In a multivariable lin-
ear regression analysis the association of log transformed IS (pCS) with clinically relevant vari-
ables at baseline was assessed [5].
The primary endpoint was renal survival defined as time from baseline to the composite
event of either eGFR of<10ml/min or 50% loss in eGFR or start of RRT, whatever occurred
first, as described previously [14, 15]; if eGFR<10 or 50% loss in eGFR occurred between two
visits, linear interpolation was used to determine the “exact” point in time. As sensitivity analy-
ses, two procedures were applied to prove consistency of our results because of not having
observed the precise date of the event. First, instead of applying linear interpolation we used
the later of the two visits as occurrence of the event. Second, subjects were interval-censored
instead of linear interpolation. In the first case, analyses as described below can just be
repeated as only the event time for some subjects changed. In the second case ICPHREG SAS
procedure for interval-censored data was applied to the data with information on the two
points between which the event occured. All data were administratively censored as of June
2019. Early drop-outs were censored at last contact and reasons for drop-out are summarized.
Kaplan-Meier curves stratified by quartiles of IS or pCS levels are presented with p value of the
log-rank test and median survival time. By means of a Cox proportional hazards model the
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association of IS or pCS with renal survival was analyzed providing adjusted hazard ratio (HR)
with 95% confidence interval (CI) and p value. Different models were considered to evaluate if
adding IS or pCS to the standard model (model 0) improved model fit. Covariates of model 0
were sex, renal diagnoses, residency, and baseline levels of eGFR, age, proteinuria (log trans-
formed), SBP SDS, BMI SDS, serum albumin, hemoglobin and phosphorus. In model 1, IS or
pCS was added to the set of basic covariates. By means of a forest plot the effect (HR with 95%
CI) of IS (pCS) on renal survival was visualized for different patient characteristics (e.g. sex:
male vs. female) based on separate Cox models with IS (pCS), the respective patient character-
istic and the other remaining covariates included. Model 1 was repeated with categorized IS or
pCS (quartile groups, compare Kaplan-Meier curves). Quality of the models was compared
based on the Akaike information criterion (AIC), with lower values indicating a better fit. The
AIC value is the expected, relative distance between the fitted model and the unknown true
mechanism that generated the observed data.
A subset of patients with very high IS levels was identified by determining the upper 95%
prediction limit (UPL) in a regression of eGFR on log-transformed IS (S1 Fig) 5. All analyses
with respect to IS were carried out separately for the whole sample (total cohort) and, as sensi-
tivity analyses, for the sample excluding patients with IS levels above the 95% UPL (consoli-
dated cohort). As this was an exploratory study, p-values were interpreted descriptively and
p<0.05 was considered statistically significant. Missing values were not imputed. Data were
analyzed using SAS1 Software version 9.4 (SAS Inc. Cary/ NC, USA).
Results
Patient characteristics
Between October 2009 and August 2011 a total of 704 children were enrolled in the 4C study.
IS and pCS serum levels were measured in 604 patients with available blood samples and an
eGFR between 10–60ml/min per 1.73 m2 at baseline denoted as total cohort in the following.
Patient characteristics are given in Table 1; these are comparable to those in the entire 4C
cohort [16]. Mean age was 12.1 ± 3.3 years with a mean eGFR of 27 ± 11 ml/min per 1.73 m2.
CAKUT was the most common (70%) underlying primary renal disease.
Measurement of indoxyl sulfate and p-cresyl sulfate
Serum IS and pCS concentrations were negatively correlated with eGFR (r = -0.46 for IS and r
= -0.43 for pCS respectively). In 45 patients IS levels exceeded the 95% UPL calculated for the
total cohort. These patients had a younger age (11.2 ± 3.3 versus 12.2 ± 3.3 years) and a lower
hemoglobin (11.1 ± 1.70 versus 11.7 ± 1.64 g/l) compared to the rest of the cohort, but no
other significant differences in baseline characteristics including medication with phosphate
binders or antibiotics and iron supplementation (S1 Table). Additional sensitivity analyses
were performed excluding these patients with IS levels exceeding the 95% UPL (denoted as
consolidated cohort, S1 Fig and Table 2).
In a multivariable regression analysis (S2 Table) IS levels showed positive associations with
urea (p = 0.004) and negative associations with eGFR (p<0.001) and uric acid (p<0.001). Age,
sex, diagnosis, residency, physical activity, BMI SDS, serum phosphorus, serum albumin, uri-
nary protein/creatinine ratio and treatment with calcium-based phosphate binders, iron or
antibiotics were not associated with IS serum levels. pCS levels were positively associated with
age (p = 0.008), non-Mediterranean residency (p<0.001), serum albumin (p<0.001), urea
(p = 0.038) and iron therapy (p = 0.034) and negatively associated with the diagnosis of glo-
merulopathies (p = 0.008), eGFR (p<0.001), uric acid (p = 0.002) and physical activity (> 4
hours per week, p = 0.044).
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Progression of CKD
During a median follow up time of 2.2 years (IQR 4.3–0.8 years, maximum follow up 8.8
years), the composite renal survival endpoint was reached by 360 patients (59.6%). The median
renal survival time was 3.5 years (95% CI, 2.9–3.9). Frequency and allocation of different end-
points as well as drop-out reasons are shown in Fig 1.
Association of IS and pCS with progression of CKD
We found a significant association of serum IS and pCS concentrations with renal survival
(p<0.0001, Fig 2A and 2B). Across all patients, the median survival time was lower in patients
with IS and pCS levels in the 4th quartile (1.5 years, 95% CI [1.1, 2.0] for IS and 1.8 years, 95%
CI [1.5, 2.8] for pCS) compared to those patients in the 1st quartile (6.0 years, 95% CI [5.0, 8.4]
and 4.4 years, 95% CI [3.4, 6.0] for IS and pCS respectively). Exclusion of patients with IS levels
above the 95% UPL (consolidated cohort), resulted in an even shorter median survival time
(Fig 2C, 0.9 years, 95% CI [0.6, 1.5] of patients with IS levels in the 4th quartile).
In a multivariable Cox regression model, older age, male sex, diagnosis of tubulointerstitial
disease or post-AKI CKD as well as the presence of proteinuria, higher systolic blood pressure,
lower baseline eGFR, higher serum phosphorus, lower serum albumin and hemoglobin levels
contributed to a higher likelihood of reaching the composite endpoint (Table 3 and Model 0,
Table 1. Patient characteristics.
Age (years) 12.1 ± 3.3 n = 604
Male sex 399 (66%) n = 604






Country n = 604
GER, CH, AT 118 (20%)
FR, IT, PT 97 (16%)
PL, LT, CZ, SRB 53 (9%)
UK 35 (6%)
Turkey 301 (50%)
BMI SDS 0.08 ± 1.30 n = 604
Systolic blood pressure SDS 0.81 ± 1.37 n = 604
eGFR (ml/min) 26.6 ± 11.2 n = 604
uPCr (mg/mg) 1.3 (2.6) n = 579
Serum Albumin (g/l) 39.0 ± 6.30 n = 604
Serum phosphorus (mmol/l) 1.55 ± 0.38 n = 604
Hemoglobin (g/l) 11.6 ± 1.65 n = 594
Data shown as mean ± standard deviation, median (interquartile range) or n (%) as appropriate.
CAKUT = congenital anomalies of the kidney and urinary tract; Post-AKI = chronic kidney disease after acute
kidney injury; BMI = body mass index; eGFR = estimated glomerular filtration rate; uPCr = Urinary protein
creatinine ratio; SDS = standard deviation score. Countries: GER = Germany; CH = Switzerland; AT = Austria;
FR = France; IT = Italy; PT = Portugal; PL = Poland; LT = Lithuania; CZ = Czech Republic; SRB = Serbia;
UK = United Kingdom.
https://doi.org/10.1371/journal.pone.0240446.t001
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total cohort, Table 4). The levels of IS, but not pCS, contributed significantly to progression of
CKD (Table 4). In detail, we found a significant association of IS levels in the 4th quartile com-
pared to the 1st quartile and renal survival (Model 1b). Furthermore, after exclusion of patients
Table 2. Serum levels of indoxyl sulfate and p-cresyl sulfate according to CKD stage.
Total cohort CKD 3a CKD 3b CKD 4 CKD 5 Consolidated cohort Excluded patients
Patients (n) 604 41 174 292 97 559 45
IS mean (SD) 25.5 (86.4) 4.00 (11.7) 17.8 (65.6) 31.4 (105) 30.8 (78.3) 7.79 (9.95) 246 (218)
IS median (IQR) 5.30 (8.70) 1.40 (1.60) 3.45 (3.70) 6.25 (7.30) 13.0 (11.0) 5.00 (6.80) 178 (113)
IS quartiles
• <2.9 152 (25%) 35 (85%) 74 (43%) 39 (13%) 4 (4%) 152 (27%) 0 (0%)
• 2.9–5.3 152 (25%) 4 (10%) 58 (33%) 85 (29%) 5 (5%) 152 (27%) 0 (0%)
• 5.3–11.6 151 (25%) 0 (0.0%) 24 (14%) 98 (33%) 29 (30%) 151 (27%) 0 (0%)
• >11.6 149 (25%) 2 (5%) 18 (10%) 70 (24%) 59 (61%) 104 (19%) 45 (100%)
Patients (n) 604 41 174 292 97 604 0
pCS mean (SD) 21.1 (18) 6.99 (6) 13.5 (11.2) 22.4 (16.1) 36.7 (22) 21.1 (18)
pCS median (IQR) 17.2 (22) 6.20 (7) 9.80 (15.2) 19.7 (19.7) 34.1 (30) 17.2 (22)
pCS quartiles
• <7.9 153 (25%) 26 (63%) 67 (39%) 49 (17%) 11 (11%) 153 (25%)
• 7.9–17.2 149 (25%) 13 (32%) 53 (31%) 74 (25%) 9 (9%) 149 (25%)
• 17.2–29.6 151 (25%) 1 (2%) 41 (24%) 92 (32%) 17 (18%) 151 (25%)
• >29.6 151 (25%) 1 (2%) 13 (8%) 77 (26%) 60 (62%) 151 (25%)
Serum levels of indoxyl sulfate (IS) and p-cresyl sulfate (pCS) in the total cohort and across CKD stage 3–5 at study entry. For survival analyses, patients were grouped
according to IS and pCS quartiles respectively. In the consolidated cohort, patients with IS levels > 95% of the upper prediction limit were excluded. IS and pCS serum
levels in μmol/l. CKD = chronic kidney disease; IS = indoxyl sulfate; pCS = p-cresyl sulfate; SD = standard deviation; IQR = interquartile range.
https://doi.org/10.1371/journal.pone.0240446.t002
Fig 1. Study description with progression to primary endpoint and reasons for drop out. eGFR = estimated
glomerular filtration rate; RRT = renal replacement therapy.
https://doi.org/10.1371/journal.pone.0240446.g001
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Fig 2. Renal survival in children with CKD according to quartiles of serum indoxyl sulfate (panels A, C) and p-cresyl
sulfate (panel B). Results for total cohort (n = 604) are given in panels A and B. Panel C shows renal survival analysis by
indoxyl sulfate quartiles after exclusion of patients with serum indoxyl sulfate above the 95% upper prediction limit
(consolidated cohort, n = 559). Indoxyl sulfate and p-cresyl sulfate serum levels are given in μmol/l. Q1-4 indicate
distribution quartiles.
https://doi.org/10.1371/journal.pone.0240446.g002
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Table 3. Multivariable Cox regression model of variables associated with renal survival without indoxyl sulfate and p-cresyl sulfate (model 0, total cohort).
Variable Estimate Standard Error p-value Hazard Ratio 95% Hazard Ratio Confidence
Intervall
Female sex -0.24 0.12 0.049 0.79 0.62 0.10
Age (years) 0.08 0.02 < .001 1.09 1.05 1.13
Diagnosis
Glomerulopathies 0.24 0.22 0.261 1.28 0.83 1.96
Post-AKI 0.85 0.27 0.001 2.34 1.40 3.91
Other 0.18 0.30 0.558 1.19 0.66 2.16
Tubulointerstitial 0.74 0.16 < .001 2.10 1.54 2.87
Non-Mediterranean 0.12 0.12 0.309 1.13 0.89 1.43
BMI SDS -0.02 0.05 0.682 0.98 0.90 1.07
Systolic BP SDS 0.15 0.04 0.001 1.17 1.08 1.26
eGFR (ml/min/1.73m2) -0.08 0.01 < .001 0.93 0.91 0.94
uPCr (mg/mg) 0.34 0.06 < .001 1.40 1.24 1.57
Hemoglobin (g/l) -0.14 0.04 < .001 0.87 0.81 0.94
Serum phosphorus (mmol/l) 0.39 0.15 0.010 1.47 1.10 1.98
Serum albumin (g/l) -0.06 0.01 < .001 0.94 0.92 0.96
Cox Model for the total cohort with variables measured at study entry (n = 569 patients). Diagnostic groups were compared to patients with the diagnosis of CAKUT.
Non-Mediterranean residency was compared to patients living in Mediterranean countries. CAKUT = congenital anomalies of the kidney and urinary tract; Post-
AKI = chronic kidney disease after acute kidney injury; BMI = body mass index; eGFR = estimated glomerular filtration rate; uPCr = Urinary protein creatinine ratio;
SDS = standard deviation score.
https://doi.org/10.1371/journal.pone.0240446.t003
Table 4. Multivariable Cox proportional hazard analysis for the association of IS and pCS serum levels with renal survival.
AIC Parameter Estimate Standard Error p-value Hazard Ratio 95% Hazard Ratio
Confidence Intervall
Model 0 total cohort 3412.5 --- --- --- ---
Model 1a 3412.2 Log IS 0.07 0.04 0.131 1.07 0.98 1.17
Model 1b 3400.3 Q2: 2.9–5.3 0.15 0.18 0.426 1.16 0.80 1.65
Q3: 5.3–11.6 -0.15 0.19 0.422 0.86 0.59 1.25
Q4: >11.6 0.48 0.19 0.011 1.62 1.12 2.35
Model 1c 3414.1 Log pCS -0.037 0.06 0.533 0.96 0.86 1.08
Model 1d 3416.7 Q2: 7.9–17.2 -0.22 0.17 0.201 0.80 0.57 1.12
Q3: 17.2–29.6 -0.17 0.18 0.317 0.84 0.60 1.18
Q4: >29.6 -0.13 0.18 0.464 0.88 0.61 1.25
Model 0 consolidated cohort 3088.5 --- --- --- ---
Model 1e 3083.9 Log IS 0.20 0.08 0.001 1.23 1.05 1.43
Model 1f 3072.4 Q2: 2.9–5.3 0.17 0.18 0.371 1.18 0.82 1.69
Q3: 5.3–11.6 -0.10 0.20 0.600 0.90 0.62 1.32
Q4: >11.6 0.66 0.21 0.002 1.94 1.29 2.93
Model 0 represents a Cox model with sex, age, diagnosis, region of residence, body mass index SDS, blood pressure SDS, estimated glomerular filtration rate, urinary
protein creatinine ratio, hemoglobin, serum phosphorus and albumin as covariates, calculated either for the total cohort (n = 569) or for the consolidated cohort
(excluding patients with IS levels exceeding the 95% upper prediction limit, n = 526). Model 1a includes serum IS, 1b IS quartiles, 1c serum pCS and 1d serum pCS
quartiles as a covariate to model 0. Models 1e and 1 f include serum IS and serum IS quartiles respectively as covariates to model 0 in the consolidated cohort. IS and
pCS are used as logarithmic values in all models. For all variables associated with renal survival (model 0, total cohort) please refer to Table 3. IS = indoxyl sulfate;
pCS = p-cresyl sulfate; Q = quartiles of serum IS and pCS levels, respectively; AIC = Akaike information criterion.
https://doi.org/10.1371/journal.pone.0240446.t004
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with IS levels >95% UPL, IS as a continuous variable (Model 1e) was significantly associated
with renal survival. The effect on renal survival of IS levels in the 4th quartile compared to the
1st quartile was even higher in patients of the consolidated cohort compared to patients of the
total cohort (Model 1f, HR 1.94, 95% CI [1.29, 2.93] versus Model 1b, HR 1.62, 95% CI [1.12,
2.35]). Similar results were obtained for the additional sensitivity analyses without linear inter-
polation where the precise date of the event was not observed by taking the date of the later
visit (S3 Table) or by considering interval censoring (S4 Table).
For the consolidated cohort, the effect of IS on renal survival in the different subsets
adjusted for the other covariates is presented in Fig 3 by means of a forest plot. We found an
interaction of IS levels with baseline CKD stage on renal survival, the highest hazard ratio
being present in patients with CKD stage 5 at enrolment. Furthermore, the excess risk attribut-
able to high IS concentrations was significantly elevated in normal-weight and normotensive,
female and older patients, patients with CAKUT and those with non-Mediterranean
residency.
Discussion
In this exploratory analysis we provide the first data showing the impact of microbial derived
uremic toxins on the progression of CKD in a representative multicenter cohort of children
with CKD. We found a significant association of serum IS concentrations with the prospective
progression of CKD, independent of other known traditional risk factors, i.e. baseline eGFR,
proteinuria and blood pressure. By contrast the pCS concentrations showed no association
with renal survival after adjustment for baseline eGFR.
Fig 3. Excess renal survival risk attributable to high versus low serum indoxyl sulfate levels according to patient characteristics of the
consolidated cohort. Each model was adjusted for all other covariates. Hazard ratio and 95% Confidence Limits indicate significance of
interaction between IS status and respective patient characteristic. The median split of indoxyl sulfate was at 5.3 μmol/l. P = percentile;
UPCr = urinary protein creatinine ratio.
https://doi.org/10.1371/journal.pone.0240446.g003
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There is a growing body of evidence on how IS might contribute to the progression of
CKD. In vitro, IS was shown to have direct toxic effects on tubular cells leading to increased
levels of oxidative stress, fibrosis and inflammation [7, 17]. In animal models, IS seems to
accelerate CKD progression by nephrotoxic effects [17]. Furthermore, vascular effects of IS
might also contribute to progression of CKD. IS promotes vascular calcification [18] and
inflammation [19] in vitro and in animal models of CKD [20]. Moreover, serum IS levels are
associated with the surrogate markers of cardiovascular disease (intima media thickness and
pulse walve velocity) in children [5] and with diminished endothelial function in adults with
CKD [21]. Accordingly, the toxicity of IS in vitro and in animal models depends on its concen-
tration, and this is reflected by the fact that those patients with IS levels in the 4th quartile have
the highest risk for progression of CKD [22]. In the only clinical study in adult patients investi-
gating the impact of IS and pCS serum levels on progression of CKD [10], 269 patients were
followed up for 21 months; only 35 patients progressed to ESKD or had a decline in eGFR of
50% or more. In that group with progressive disease, there was a significant association of both
IS and pCS serum concentrations with renal survival. However, almost half of the patients had
diabetes, which is known to have a significant impact not only on the progression of CKD but
also on the serum levels of uremic toxins [23]. Recently, it has been shown that lower kidney
clearance of six endogenous solutes, including IS, but not pCS, are associated with a higher
risk of CKD progression in adults participating in the CRIC study [24], which is in line with
our results. In our study we provide the first results about the association of IS with progres-
sion of CKD in pediatric patients who had no other comorbidities which might interfere with
renal survival. This allows to attribute the effect on renal survival more directly to serum con-
centrations of uremic toxins. This may explain why we identified a significant association with
IS but not with pCS.
Our large study population permitted further statistical analysis of the relative contribution
of IS levels to renal survival. The impact of IS levels increased with each stage of CKD, which is
most likely due to accumulation of IS with progressive decrease of eGFR [5]. However, IS
serum levels also showed interactions with other risk factors for progression. Thus, high IS lev-
els were still associated with a moderately increased hazard ratio for renal progression in the
presence of proteinuria, a diagnosis of CAKUT and for older patients. These are interesting
findings as we have shown, that diagnosis of CAKUT itself had no direct influence on IS levels
(S2 Table). Moreover, antibiotic treatment was more frequent in patients with CAKUT (29%
of patients with CAKUT received antibiotic treatment or prophylaxis within six week before
recruitment, S5 Table) compared to other patients (p<0.001), but antibiotics were not inde-
pendently associated with IS levels. Thus the reason for the enhanced effect of IS in patients
with CAKUT remains unexplained.
Proteinuria and low serum albumin are well known risk factors for progression of CKD,
but neither proteinuria nor serum albumin were independently associated with IS levels. Nev-
ertheless, IS was associated with a slightly higher hazard ratio for progression of CKD in
patients with proteinuria, while the effect of IS on progression depending on serum albumin
was decreased in hypoalbuminemia. Although we can not provide data about residual diuresis,
measurement of free serum toxin concentrations or urinary toxins concentrations, these find-
ings allow speculations about a higher fraction of free and therefore toxic serum concentra-
tions of IS in patients with proteinuria and hypoalbuminemia. For female patients, our data
show a lower hazard ratio than for male patients, i.e. better renal survival, but a significantly
higher impact of higher serum levels of IS on renal survival.
Interestingly, the impact of higher IS levels on renal survival was stronger in patients with
controlled blood pressure than in hypertensive patients; this finding could indicate that better
blood pressure control during follow up, which occurred in this cohort (unpublished
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observation), led to “unmasking” of the effect of higher IS levels. Furthermore, a higher
BMI-SDS was associated with better renal survival in the multivariable model, and the relative
contribution of high IS levels to renal survival showed the highest hazard ratio in underweight,
possibly malnourished patients. While obesity is regarded as an independent risk factor for
progression of CKD in adults and children [25, 26], our data indicate the need for further stud-
ies regarding the role of uremic toxins in modulating progression of CKD in obese and non-
obese patients. Taken together, our findings highlight the impact of elevated IS levels on renal
survival and provide new insights into the pathophysiology of CKD progression in the absence
of known risk factors such as obesity and arterial hypertension.
Therapeutic efforts to decelerate progression of CKD by lowering serum IS levels have so
far been unsuccessful. A reduction of IS levels by administration of the oral adsorbent AST-
120 had no significant effect on renal survival in clinical trials [27–29]. This might be explained
by the complex interplay of nutrition and the gut microbiome, both of which essentially con-
tribute to the balance of beneficial metabolites, e.g. short chain fatty acids (SCFAs), and harm-
ful metabolites, e.g. uremic toxins, in CKD. Removal of uremic toxins by dialysis modalities,
including intensified hemodialysis, is insufficient [30]. However, it has been shown that the
administration of pre- and probiotics as well as SCFAs has beneficial effects on the gut micro-
biome and decreases the uremic toxin burden in vivo [31, 32]. Animal work has suggested that
these effects of pre- and probiotics might also attenuate progression of CKD [33]. Therefore,
studies using a combination of different treatment modalities such as microbiome-centered
therapies (to restore a protective balance in microbiome composition and metabolism) and
effective elimination strategies of uremic toxins are needed.
There are several limitations of our analysis. First, the 4C study was not designed specifi-
cally to evaluate the effect of microbial derived uremic toxins, but more general effects on pro-
gression of CKD. It is known that serum levels of gut-derived uremic toxins, such as IS and
pCS, are potentially confounded by various factors such as age, diabetes, obesity and metabolic
syndrome, which have a direct impact on the composition and function of the gut microbiome
and hence, on microbial metabolism [34, 35]. Furthermore, antibiotic treatment is supposed
to have an influence on serum levels of uremic toxins as well [31, 36]. Wherever possible, these
factors have been addressed and included to our multivariable models. Nevertheless, it is
unclear why some of our patients had extremely high serum levels of IS, but not pCS, above the
95% UPL. There were no significant differences between these patients and the rest of the
cohort regarding baseline characteristics, including the frequency of antibiotic treatment or
prophylaxis. We cannot completely rule out any pre-analytical bias in sampling, storage or
transport to our central laboratory. However, the association of serum IS levels with renal sur-
vival was even stronger after exclusion of these patients. Furthermore, we have no information
about symptomatic or asymptomatic gastrointestinal disorders. Nutrition and especially protein
intake have an influence on microbial metabolism [37, 38] and have been associated with intra-
patient variability, as described previously [39]. Although we have no data about nutrition and
dietary intake in the 4C-study, we used Mediterranean residency as a surrogate parameter for
nutrition. Furthermore, IS and pCS levels were measured only once at study entry, so we are
not able to analyze the impact of nutrition on intra-patient variability in more detail.
Finally, we acknowledge the risk of attrition bias as a consequence of the high drop-out rate
during our study follow up, limiting the power of our statistical analysis. On the other hand,
the large number of patients enrolled in this study and the choice of a composite endpoint
enables us to show a significant association of IS with progression of CKD for the first time in
children.
In conclusion, our study shows a significant association of serum IS, but not pCS, with the
progression of CKD in children, independent of other known risk factors such as baseline
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GFR, blood pressure and proteinuria. These results highlight the unmet need of effective elimi-
nation strategies to lower the uremic toxin burden, especially in patients with advanced CKD
stages, in order to abate the progression of CKD.
Supporting information
S1 Fig. Log-transformed serum levels of indoxyl sulfate (A) and p-cresyl sulfate (B) are corre-
lated with eGFR in 604 children with chronic kidney disease at study entry. Linear regression
of log-transformed serum levels of indoxyl sulfate (IS) and p-cresyl sulfate (pCS) showed a sig-
nificant correlation with eGFR (Pearson correlation coefficient r = -0.46 for IS and r = -0.43
for pCS). 45 patients had IS levels above the 95% upper prediction limit (UPL). While no
patients had pCS levels above the 95% UPL, some patients had pCS levels below the 95% lower
prediction limit.
(PDF)
S1 Table. Patient characteristics of patients with indoxyl sulfate levels exceeding the 95%
upper prediction limit compared to the rest of the cohort (consolidated cohort). Data
shown as mean ± standard deviation, median (interquartile range) or n (%) as appropriate. p-
value indicates group difference between consolidated cohort and those patients with IS levels
exceeding the 95% UPL. IS = indoxyl sulfate; UPL = upper prediction limit; CAKUT = con-
genital anomalies of the kidney and urinary tract; Post-AKI = chronic kidney disease after
acute kidney injury; BMI = body mass index; eGFR = estimated glomerular filtration rate;
uPCr = Urinary protein creatinine ratio; SDS = standard deviation score; Non-Ca phosphate
binders = non calcium containing phosphate binders; Ca phosphate binders = calcium con-
taining phosphate binders. Countries: GER = Germany; CH = Switzerland; AT = Austria;
FR = France; IT = Italy; PT = Portugal; PL = Poland; LT = Lithuania; CZ = Czech Republic;
SRB = Serbia; UK = United Kingdom.
(PDF)
S2 Table. Multivariable linear regression models of variables associated with serum levels
of indoxyl sulfate and p-cresyl sulfate in 604 children with CKD at baseline. Diagnostic
groups were compared to patients with the diagnosis of CAKUT. Residency was defined as liv-
ing in Mediterranean or Non-Mediterranean countries. Physical activity was compared to
being physically inactive (0 hours). SE = standard error; CAKUT = congenital anomalies of
the kidney and urinary tract; Post-AKI = chronic kidney disease after acute kidney injury;
BMI = body mass index; eGFR = estimated glomerular filtration rate; Ca-based P binders =
calcium-based phosphate binders; uPCr = Urinary protein creatinine ratio; SDS = standard
deviation score.
(PDF)
S3 Table. Multivariable Cox proportional hazard analysis for the association of IS and pCS
serum levels with renal survival (sensitivity analysis by taking the later visit if the event
occurred between two visits). Survival analysis using the PHREG SAS procedure. If the event
occurred between two visits the later of the two visits was taken as occurrence of the event
instead of using linear interpolation. Model 0 represents a Cox model with sex, age, diagnosis,
region of residence, body mass index SDS, blood pressure SDS, estimated glomerular filtration
rate, urinary protein creatinine ratio, hemoglobin, serum phosphorus and albumin as covari-
ates, calculated either for the total cohort (n = 569) or for the consolidated cohort (excluding
patients with IS levels exceeding the 95% upper prediction limit, n = 526). Model 1a includes
serum IS, 1b IS quartiles, 1c serum pCS and 1d serum pCS quartiles as a covariate to model 0.
Models 1e and 1 f include serum IS and serum IS quartiles respectively as covariates to model
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0 in the consolidated cohort. IS and pCS are used as logarithmic values in all models. For all
variables associated with renal survival (model 0, total cohort) please refer to Table 3.
IS = indoxyl sulfate; pCS = p-cresyl sulfate; Q = quartiles of serum IS and pCS levels, respec-
tively.
(PDF)
S4 Table. Multivariable Cox proportional hazard analysis for the association of IS and pCS
serum levels with renal survival (sensitivity analysis by considering interval censoring if
the event occurred between two visits). Survival analysis for interval-censored data using the
ICPHREG SAS procedure. Model 0 represents a Cox model with sex, age, diagnosis, region of
residence, body mass index SDS, blood pressure SDS, estimated glomerular filtration rate, uri-
nary protein creatinine ratio, hemoglobin, serum phosphorus and albumin as covariates, cal-
culated either for the total cohort (n = 569) or for the consolidated cohort (excluding patients
with IS levels exceeding the 95% upper prediction limit, n = 526). Model 1a includes serum IS,
1b IS quartiles, 1c serum pCS and 1d serum pCS quartiles as a covariate to model 0. Models 1e
and 1 f include serum IS and serum IS quartiles respectively as covariates to model 0 in the
consolidated cohort. IS and pCS are used as logarithmic values in all models. For all variables
associated with renal survival (model 0, total cohort) please refer to Table 3. IS = indoxyl sul-
fate; pCS = p-cresyl sulfate; Q = quartiles of serum IS and pCS levels, respectively.
(PDF)
S5 Table. Antibiotic therapy at baseline and within 6 weeks before baseline stratified by
diagnosis group. CAKUT = congenital anomalies of the kidney and urinary tract.
(PDF)
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Litwin, MD, and Anna Nimierska, MD; Serviçio de Pediatria, Hospital de São João, Porto, Por-
tugal: Ana Teixeira, MD; University Chil-dren’s Hospital, Belgrade, Serbia: Amira Peco-Antic,
MD, and Dusan Paripovic, MD; Nephrology, University Children’s Hospital, Zürich, Switzer-
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Centre de Reference Maladies Re-nales Rares du Sud-Quest, Bordeaux, France: Jerome Har-
ambat, MD; Pediatric Nephrology, Zabrze, Poland: Maria Szczepanska, MD; Dortcelik Chil-
dren’s Hospital, Bursa, Turkey: Hakan Erdogan, MD; Uludag University, Bursa, Turkey:
Osman Donmez, MD; Department of Pediatric Nephrology, University of Gaziantep, Gazian-
tep, Turkey: Ayse Balat, MD; Tepecik Training and Research Hospital, Izmir, Turkey: Nejat
Aksu, MD; Department of Pediatric Nephrology, Inonu Universtiy Medical School, Malatya,
Turkey: Yilmaz Tabel, MD; Pediatric Nephrology Department, Celal Bayar University,
Manisa, Turkey: Pelin Ertan, MD; and Pediatric Nephrology, Sanliurfa Children’s Hospital,
Sanliurfa, Tur-key: Ebru Yilmaz, MD.
Author Contributions
Conceptualization: Johannes Holle, Karolis Azukaitis, Rainer Büscher, Hakan Erdogan, Uwe
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